Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
hepatitis B DNA vaccine (AnGes, Inc.)
- Development stage
- Preclinical
- Lead developer
- AnGes
- Modality
- DNA Vaccines → Plasmid DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Prophylactic Vaccines → Vaccines & Immunotherapeutics, Gene Therapies
- Administration
- Intramuscular, Intradermal
01
Overview
The hepatitis B DNA vaccine is an experimental therapeutic candidate being developed by AnGes, Inc. in collaboration with Osaka University for the treatment of chronic hepatitis B. Utilizing AnGes's proprietary DNA vaccine platform, the drug consists of a plasmid DNA vector designed to express specific hepatitis B virus (HBV) antigens within host cells. Upon administration, the plasmid enters the cells and triggers the production of viral proteins, which are then presented to the immune system to induce a robust, multi-specific immune response. This approach aims to overcome the immune exhaustion and tolerance characteristic of chronic HBV infection, stimulating both cytotoxic T-lymphocyte activity and antibody production to facilitate viral clearance and achieve a functional cure. As of 2024, the project remains in the preclinical research phase.
- Other names
- Hepatitis B DNA vaccineChronic hepatitis B DNA vaccine candidate
Beyond the preview
Go deeper on hepatitis B DNA vaccine (AnGes, Inc.).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on hepatitis B DNA vaccine (AnGes, Inc.).